Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

PHASE3CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 17, 2016

Study Completion Date

October 31, 2016

Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
DRUG

Ciprofloxacin dispersion for inhalation

DRUG

Placebo

Trial Locations (109)

Unknown

Peoria

Phoenix

Downey

Los Angeles

Poway

Farmington

Washington D.C.

Celebration

Kissimmee

Miami

Sebring

Kailua

Chicago

Columbia

Royal Oak

Rochester

Lincoln

Cedar Knolls

New Hyde Park

New York

Syracuse

Charlotte

Huntersville

Oklahoma City

Anderson

Charleston

Columbia

Fort Worth

Tyler

Falls Church

Concord

Westmead

Brisbane

Cairns

South Brisbane

Daw Park

Footscray

Heidelberg

Adelaide

Calgary

Kelowna

Montreal

Borstel

Berlin

Donaustaff

Freiburg im Breisgau

Hanover

Immenstadt im Allgäu

Lübeck

Munich

Budapest

Debrecen

Miskolc

Szombathely

Dublin

Galway

Ashkelon

Haifa

Holon

Jerusalem

Kfar Saba

Rehovot

Tel Aviv

Pavia

Acquaviva delle Fonti

Bologna

Ferrara

Florence

Milan

Pisa

Cekule

Daugavpils

Liepāja

Riga

Bialystok

Chrzanów

Warsaw

Wroclaw

Bucharest

Constanța

Timișoara

Durban

Pietermaritzburg

Cape Town

eManzimtoti

Krugersdorp

Busan

Seoul

Palma de Mallorca

Barcelona

Girona

Madrid

Málaga

Kaohsiung City

Taichung

Taipei

Glasgow

Birmingham

Bradford

Dundee

Liverpool

Llandough

London

Manchester

Newcastle upon Tyne

Nottinghamshire

Stoke-on-Trent

Tyne and Wear

Wolverhampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Grifols Therapeutics LLC

INDUSTRY

lead

Aradigm Corporation

INDUSTRY